Delaying the Onset of Nearsightedness Until Treatment Study

Summary

Participants eligible for the study will be randomized to one of three concentrations of atropine and followed for a month.

Conditions

• Myopia

Interventions

DRUG

Atropine Ophthalmic

eye drops to be administered once daily

Sponsors & Collaborators

• University of Houston

  collaborator OTHER

• State University of New York

  collaborator OTHER

• Pennsylvania College of Optometry

  collaborator INDUSTRY

• Southern California College of Optometry at Marshall B. Ketchum University

  collaborator OTHER

• University of California, Berkeley

  collaborator OTHER

• Stanford University

  collaborator OTHER

• Case Western Reserve University

  collaborator OTHER

• Illinois College of Optometry

  collaborator OTHER

• Indiana University

  collaborator OTHER

• New England College of Optometry

  collaborator OTHER

• University of the Incarnate Word

  collaborator OTHER

• Southern College of Optometry

  collaborator OTHER

• University of Missouri, St. Louis

  collaborator OTHER

• Ohio State University

  lead OTHER

Principal Investigators

• Jeffrey J Walline, OD PhD · Ohio State University

Study Design

Allocation

RANDOMIZED

Purpose

OTHER

Masking

QUADRUPLE

Model

PARALLEL

Eligibility

Min Age

6 Years

Max Age

11 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2024-01-01

Primary Completion

2024-08-31

Completion

2024-08-31

FDA Drug

Yes